熱門資訊> 正文
Bristol Myers获得Breyanzi标签扩张的优先审查
2025-08-05 05:39
- Bristol Myers Squibb (NYSE:BMY) said that the U.S. FDA has accepted the expanded label application for its cell therapy, Breyanzi, as a potential treatment for relapsed or refractory marginal zone lymphoma with at least two prior lines of systemic therapy.
- The FDA has granted the application target action date of December 5, 2025.
- Breyanzi is approved in the U.S. for the treatment of relapsed or refractory large B-cell lymphoma
More on Bristol-Myers Squibb Company
- Bristol-Myers Squibb: Buy The Weakness
- Bristol-Myers Squibb: Declines Have Gone Too Far
- Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat
- Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week
- Bristol-Myers Squibb shares snapped six-session losing streak
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
